Shahid Beheshti University of Medical Sciences, Iran
Keynote: J Cancer Sci Ther
IORT is an accepted standard treatment for early stages of breast cancer in selected Cases.This is proven in two large trials: ELIOT and TARGIT-A based on electron high voltage beam and low kvX-ray energy respectively. Published results of the two trials aimed at evaluating local recurrence as the final outcome. In ELIOT study the local recurrence rate is % 4/4 versus 0.4% in the patients who received IORT and EBRT, in comparison to 3.2% and 1.3% in TARGIT-A trial, these differences needs to be under more consideration regarding the efficacy and beneficence of IORT. Hereby we are going to analyze the data of these two trials to confirm the strategy of IORT in breast cancer as boost or radical modalities.Patient selection according to classification of ASRTO or ESTRO guidelines confirmed the local recurrence rate of IOERT(ELIOT) in low risk patients similar to TARGIT decrease to less than 1.9%.This rate is less than the rate of local recurrence of EBRT in other studies in the world.Statistical analysis revealed that in patients of both trialwith matchingclinical, pathological and biological profilefor both methods,theradicalIORTusingelectronandLow kvX-rayare effectiveandacceptable.It seems in patients with low risk factors, IORT is more effective than EBRT, we compared ELIOT andTARGIT-ATrialdocumentsandfoundallofsimilarityand difference and referred to these two trials recommending using IORT for selected cases of breast cancer with at least non inferiority in DFS,OS, with superiority in cosmetic, non breast death and more.
Nahid Nafissi received her MD and general surgery in 1998 from Iran University of Med Sci. She received her Post graduate degree in breast surgery from Europe. She has been an active member of Cancer Research Center (CRC), SB Univ. of Med Sci. (SBMU) since 2006. She is a member of the Iranian intraoperative radiotherapy (ISIORT) NGO. She has published more than 28 papers in reputable journals.She has been organizing Breast Oncoplasty workshops yearly during the International Breast Congress in Iran. She is now engaged in a fellowship subspeciality in breast onco-surgery at the CRC, SBMU.